HTB homepage • Conference reports • Articles by subject • Subscribe August 2018 Contents Editorial 24 August 2018: vol 19 no 14: AIDS 2018 – next reports… 03 August 2018: vol 19 no 13: AIDS 2018 – first reports Conference reports 22nd International AIDS Conference (AIDS 2018) – second reports Namibia close to achieving 90-90-90 targets Dolutegravir monotherapy: still no longer recommended in either research or clinical practice Changing comorbidities in HIV positive people older than 60 at London clinic High acceptability of annual digital (finger) exam for early detection of anal cancer in gay men >35 years old High rates of anal HPV infection in gay men using PrEP in IPERGAY: the role of vaccination HCV incidence and reinfection in HIV negative gay men using PrEP in the Netherlands FDA-approved compounds that might selectively reverse HIV latency Lack of impact on viral reservoir with α4β7 monoclonal antibody vedolizumab: macaque results not matched in humans Janssen HIV vaccine: update from APPROACH and largescale efficacy study Viral load testing in Latin America and the Caribbean Access to viral load testing increased from 14% to 61% over two years in Côte d’Ivoire Resolving a diagnosis for people with persistently indeterminate HIV test results 10th International Workshop on HIV Paediatrics – second reports Dolutegravir dispersible tablets for infants and young children: early PK, safety and efficacy 22nd International AIDS Conference (AIDS 2018) – first reports Caution on press conference news from AIDS 2018 Zero HIV transmissions in PARTNER 2 study after gay couples had sex 77,000 times without condoms – an undetectable viral load stops HIV DTG/3TC dual therapy is non-inferior to triple-ART in GEMINI study Once-daily reduced dose darunavir/ritonavir (400 mg/100 mg) is non-inferior to twice-daily lopinavir/ritonavir in South African switch study Superior efficacy with dolutegravir-based ART compared with other regimens at 6 months: real-world data from Brazil WHO recommends dolutegravir widely but women’s access will depend on contraception provision (2018) No additional neural tube defects among a further 170 preconception dolutegravir exposures in Botswana: Tsepamo study (July 2018) Swifter viral load suppression with dolutegravir vs efavirenz in late pregnancy: results from DolPHIN-1 First randomised kick-and-kill cure study fails to reduce HIV reservoir: RIVER study reports vorinostat and vaccines show activity, but not enough Using PrEP with feminising hormone therapy supports daily PrEP dosing for transwomen Daily and on-demand PrEP both prevent HIV in Prévenir study: high adherence by gay Parisians AIDS 2018 online: links to selected webcasts 10th International Workshop on HIV Paediatrics – first reports Preconception safety signal with dolutegravir: data from the Tsepamo study Antiretrovirals Top-line phase 3 results released for cabotegravir/rilpivirine long-acting injections Interactions between oral anticoagulants and Genvoya, Stribild and cobicistat: FDA label updates Other news More than ten people a day died from drug-related deaths in England and Wales last year: On the web We learn, we think, we change: Martin Fisher Foundation and Stiggy launch campaign to end stigma PDFs 24 August 2018: vol 19 no 14 03 August 2018: vol 19 no 13 HTB homepage • Conference reports • Articles by subject • Subscribe
